Adenovirus Based Virotherapy Market Size & Share, by Type (Oncolytic Adenoviruses, Gene Therapy Vectors), End User (Hospitals, Research Institutes, Biopharmaceutical) - Global Supply & Demand Analysis & Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3118
  • Published Date: Nov 24, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Adenovirus Based Virotherapy Market size is anticipated to reach USD 27 billion by the end of 2036, growing at a CAGR of 6% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of adenovirus based virotherapy was over USD 13 billion. The development and growth of the market is fueled by several factors, including ongoing clinical trials, regulatory approvals, and the commercialization of virotherapies. Positive results from clinical trials demonstrating the safety and efficacy of adenovirus-based virotherapy in treating certain types of cancer significantly drive market growth. Successful clinical outcomes contribute to regulatory approvals and increased industry interest. Along with these, escalating research & development concerned with adenovirus and surging demand for vector-based therapies are also projected to drive market growth in the coming years. Furthermore, rising government investments to spread awareness about early cancer detection are expected to provide ample growth opportunities to the market in the near future.

Adenovirus-based virotherapy involves the use of adenoviruses, which are common viruses that can cause respiratory and other infections in humans, as vectors to deliver therapeutic genes into cancer cells. These viruses are modified to selectively replicate in and destroy cancer cells while sparing normal, healthy cells. Obtaining regulatory approvals from agencies such as the FDA or EMA for adenovirus-based virotherapies is a critical factor for market growth. Regulatory clearance enables companies to bring their products to market and increases confidence among healthcare professionals and patients.

Adenovirus Based Virotherapy Market Overview
Get more information on this report: Request Free Sample PDF

Adenovirus Based Virotherapy Sector: Growth Drivers and Challenges

Growth Drivers

  • Advancements in Oncolytic Virotherapy Research: The adenovirus based virotherapy market has witnessed significant growth driven by ongoing advancements in oncolytic virotherapy research. According to industry experts, the relentless pursuit of understanding the complex interactions between viruses and cancer cells has propelled the development of novel therapeutic approaches. Research studies, such as those published in reputable journals like the Journal of Virology and Cancer Research, have demonstrated the potential of adenovirus-based virotherapy in selectively targeting and eliminating cancer cells. The intricate understanding of viral biology and the ability to engineer adenoviruses for enhanced tumor specificity have paved the way for innovative treatment modalities. For example, recent breakthroughs in genetic engineering techniques have enabled researchers to modify adenoviruses to carry therapeutic genes directly to cancer cells, minimizing damage to healthy tissues. Research investment in oncolytic virotherapy has surged by 60% over the past five years, indicating a robust commitment to advancing this field. Major academic institutions, pharmaceutical companies, and biotech firms have allocated substantial resources to propel virotherapy research forward, leading to an increasing number of pre-clinical and clinical trials.
  • Increasing Prevalence of Cancer: The rising prevalence of cancer has been a fundamental driver for the adenovirus based virotherapy market, with an alarming increase of approximately 10% in global cancer incidence over the past decade. As conventional treatments face limitations in addressing the complexities of certain cancers, the demand for innovative and targeted therapies like adenovirus-based virotherapy has surged. This growing patient pool has led to a corresponding increase of approximately 15% in the number of clinical trials. The market's response to the unmet medical needs in oncology is evident in the escalating number of investigational new drug applications submitted to regulatory agencies for adenovirus-based virotherapies.
  • Rising Regulatory Approvals: Regulatory approvals have been a crucial driver for the adenovirus based virotherapy market. Recognition from regulatory bodies such as the FDA and EMA not only validates the safety and efficacy of adenovirus-based treatments but also instills confidence among healthcare professionals and patients. The expedited approval timelines, attributed to the breakthrough designation granted to certain virotherapies, have resulted in a significant reduction in time from initial clinical trials to market availability. The streamlined regulatory pathway has attracted pharmaceutical giants, contributing to the growth in licensing agreements between virotherapy developers and established industry leaders.


  • Host Immune Response: Adenoviruses, even when modified for therapeutic use, can trigger immune responses in the host. The immune system may recognize and eliminate the viral vectors before they effectively reach and treat cancer cells. This challenge can limit the efficacy of virotherapy and may require additional strategies to evade or modulate the immune response. The adaptive immune response involves the activation of T cells and B cells, leading to the development of specific immune memory. If an individual has been previously exposed to adenoviruses (due to natural infection or vaccination), they may have pre-existing immunity. Pre-existing immunity can neutralize adenoviral vectors before they reach the tumor site. This recognition can reduce the effectiveness of virotherapy and limit its applicability in individuals with prior adenovirus exposure.
  • Limited Tumor Specificity
  • Vector Delivery Challenges

Adenovirus Based Virotherapy Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 13 Billion

Forecast Year Market Size (2036)

~ USD 27 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Adenovirus Based Virotherapy Segmentation

Type (Oncolytic Adenoviruses, Gene Therapy Vectors)

The oncolytic adenoviruses segment in the adenovirus based virotherapy market is estimated to gain the largest revenue share of 60% in the year 2036. Oncolytic adenoviruses represent a cutting-edge approach in cancer therapy, leveraging the inherent ability of adenoviruses to infect and destroy cancer cells selectively. Several key drivers influence the growth of the oncolytic adenoviruses segment. One of the primary drivers propelling the growth of oncolytic adenoviruses is the relentless pursuit of advancements in virotherapy research. The increase in research investments underscores the commitment of the scientific community to explore and harness the potential of oncolytic adenoviruses in cancer treatment. Investments in oncolytic virotherapy research have witnessed an annual increase of 30% over the past five years, totaling USD 1.5 billion in the year 2022. Researchers are delving deep into understanding the intricate interactions between oncolytic adenoviruses and cancer cells. This includes refining the genetic modifications of adenoviruses to enhance tumor specificity and optimizing delivery mechanisms to improve their reach within tumor masses. Breakthroughs in virotherapy research are contributing to the development of safer, more potent oncolytic adenoviruses, driving the segment's growth.

End User (Hospitals, Research Institutes, Biopharmaceutical)

Adenovirus based virotherapy market from the hospitals segment is expected to garner a significant share in the year 2036. The hospitals segment plays a pivotal role in the growth and adoption of Adenovirus Based Virotherapy, serving as the primary point of access for patients seeking advanced cancer treatments. Several key drivers contribute to the growth of this segment. A significant growth driver for the hospitals segment is the escalating incidence of cancer, reflected in increase in hospital admissions. The burden of cancer has surged globally, necessitating advanced and targeted treatment modalities like Adenovirus Based Virotherapy. Hospitals, as comprehensive healthcare hubs, witness a steady influx of cancer patients seeking diagnosis, treatment, and specialized care. The rising demand for advanced therapies positions Adenovirus Based Virotherapy as a crucial component in hospitals' oncology services, fostering growth in the segment. Hospitals that comply with regulatory standards and achieve accreditation for virotherapy services demonstrate a commitment to patient safety and quality care. Accreditation fosters trust among patients, referring physicians, and regulatory bodies, positioning the hospital as a reliable provider of Adenovirus Based Virotherapy and supporting sustained growth in the segment.

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Our in-depth analysis of the global adenovirus based virotherapy market includes the following segments:


  • Oncolytic Adenoviruses
  • Gene Therapy Vectors



           End User

  • Hospitals
  • Research Institutes
  • Biopharmaceutical

Research Nester
Adenovirus Based Virotherapy Market Region
Get more information on this report: Request Free Sample PDF

Companies Dominating the Adenovirus Based Virotherapy Market

    • Amgen Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Merck & Co., Inc.
    • Novartis International AG
    • Johnson & Johnson
    • Genelux Corporation
    • PsiOxus Therapeutics
    • Oncorus, Inc.
    • SillaJen, Inc.
    • Transgene SA
    • Virttu Biologics Limited


In The News

  • In 2022, Merck merged its wholly owned subsidiary Merck Development & Commercialization Inc., a US-based pharmaceutical company, with Merck Pharmaceuticals America Inc., a US-based pharmaceutical company. The merger was aimed at streamlining operations and improving efficiency.
  • In 2022, Merck merged its wholly owned subsidiary Merck Manufacturing Division, a US-based pharmaceutical manufacturing company, with Merck Pharmaceuticals Supply Chain, a US-based pharmaceutical supply chain company. The merger was aimed at streamlining operations and improving efficiency.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3118
  • Published Date: Nov 24, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for healthcare sector is the major factor driving the market growth.

The market size of adenovirus based virotherapy is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024-2036.

The major players in the market Amgen Inc., Merck & Co., Inc., Novartis International AG, Johnson & Johnson, Genelux Corporation, PsiOxus Therapeutics, Oncorus, Inc., and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Adenovirus Based Virotherapy Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying